6-52058349-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000371117.8(PKHD1):c.1486C>T(p.Arg496Ter) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000273 in 1,614,018 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
ENST00000371117.8 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PKHD1 | NM_138694.4 | c.1486C>T | p.Arg496Ter | stop_gained | 16/67 | ENST00000371117.8 | NP_619639.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PKHD1 | ENST00000371117.8 | c.1486C>T | p.Arg496Ter | stop_gained | 16/67 | 1 | NM_138694.4 | ENSP00000360158 | P2 | |
PKHD1 | ENST00000340994.4 | c.1486C>T | p.Arg496Ter | stop_gained | 16/61 | 5 | ENSP00000341097 | A2 |
Frequencies
GnomAD3 genomes AF: 0.000618 AC: 94AN: 152150Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000665 AC: 167AN: 251220Hom.: 0 AF XY: 0.000707 AC XY: 96AN XY: 135756
GnomAD4 exome AF: 0.000237 AC: 346AN: 1461868Hom.: 0 Cov.: 32 AF XY: 0.000232 AC XY: 169AN XY: 727230
GnomAD4 genome AF: 0.000618 AC: 94AN: 152150Hom.: 0 Cov.: 32 AF XY: 0.000982 AC XY: 73AN XY: 74324
ClinVar
Submissions by phenotype
Autosomal recessive polycystic kidney disease Pathogenic:7
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 11, 2019 | NM_138694.3(PKHD1):c.1486C>T(R496*) is classified as pathogenic in the context of PKHD1-related autosomal recessive polycystic kidney disease. Sources cited for classification include the following: PMID 12506140 and 15698423. Classification of NM_138694.3(PKHD1):c.1486C>T(R496*) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, no assertion criteria provided | curation | Reproductive Health Research and Development, BGI Genomics | Jan 06, 2020 | NM_138694.3:c.1486C>T in the PKHD1 gene has an allele frequency of 0.007 in European (Finnish) subpopulation in the gnomAD database. The PKHD1 c.1486C>T (p.Arg496*) variant results in a premature termination codon, predicted to cause a truncated or absent PKHD1 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. This variant has been reported in patients with autosomal recessive polycystic kidney disease, including six homozygotes, five compound heterozygotes (with V3471G and D2761Y) (PMID: 12506140; 15698423). Taken together, we interprete this variant as Pathogenic/Likely pathogenic variant. ACMG/AMP Criteria applied: PVS1; PM3_Strong, PP4. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2003 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 25, 2016 | Variant summary: The PKHD1 c.1486C>T (p.Arg496X) variant results in a premature termination codon, predicted to cause a truncated or absent PKHD1 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g.c.9319C>T/p.Arg3107X). One in silico tool predicts a damaging outcome for this variant. This variant was found in 69/121402 control chromosomes at a frequency of 0.0005684, which does not exceed the estimated maximal expected allele frequency of a pathogenic PKHD1 variant (0.0070711). Variant was primarily detected in Finnish European population in both controls and cases, and it was reported as a founder mutation for Finnish population. In addition, multiple reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 03, 2023 | This sequence change creates a premature translational stop signal (p.Arg496*) in the PKHD1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PKHD1 are known to be pathogenic (PMID: 19940839). This variant is present in population databases (rs137852949, gnomAD 0.7%), and has an allele count higher than expected for a pathogenic variant. This premature translational stop signal has been observed in individuals with autosomal recessive polycystic kidney disease (PMID: 12506140, 19914852, 22415584, 27225849). It is commonly reported in individuals of Finnish ancestry (PMID: 12506140). ClinVar contains an entry for this variant (Variation ID: 4114). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 17, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Sep 22, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 19, 2015 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 19, 2021 | Observed multiple times with a pathogenic variant in published literature and in a patient referred for genetic testing at GeneDx, but it is not known whether the variants occurred on the same (in cis) or on different (in trans) chromosomes in all cases (Gunay-Aygun et al., 2010); Reported heterozygous in a patient with polycystic liver disease (Besse et al., 2017); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 22415584, 25525159, 12506140, 28375157, 15698423, 15200508, 20413436, 33123899) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | PKHD1: PM3:Very Strong, PVS1, PM2 - |
Polycystic kidney disease 4 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 09, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 29, 2024 | - - |
Autosomal dominant polycystic liver disease Pathogenic:1
Likely pathogenic, no assertion criteria provided | literature only | Yale Center for Mendelian Genomics, Yale University | Apr 04, 2017 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at